title: Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours.
abstract: BACKGROUND
  Hepatitis B virus (HBV) reactivation may occur with chemotherapy and has significant morbidity and mortality. The United States Centre for Disease Control and Prevention recommends pre-chemotherapy hepatitis B screening for all cancer patients, while the American Society of Clinical Oncology finds that there is insufficient evidence currently to support such a recommendation. Apart from anthracyclines, HBV reactivation rates from other commonly used chemotherapy regimens in solid tumours are not well described.
  
  
  METHODS
  We compared HBV reactivation risk in patients receiving several commonly used chemotherapy regimens for solid tumours associated with different immunosuppression risk at a tertiary cancer centre in an HBV endemic region.
  
  
  RESULTS
  A total of 1149 patients were identified, including 434, 196, 245 and 274, respectively, who received doxorubicin-based, oxaliplatin- or irinotecan-based, carboplatin/gemcitabine, and capecitabine chemotherapy. HBV screening rate was 39% overall. Thirty out of 448 (7%) screened patients were HBsAg positive and 28 out of 30 received prophylactic antiviral therapy with no reactivation. Three out of 1149 patients overall (0.3%) developed HBV reactivation, all from the unscreened doxorubicin group (3 out of 214, 1.4%). No unscreened patients (0 out of 487) in the other three treatment groups developed reactivation (P<0.001).
  
  
  CONCLUSIONS
  Not all chemotherapy regimens result in HBV reactivation. Routine hepatitis B screening for low- or moderate-risk regimens may not be warranted.
authors: Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore.
authors: W H Y
authors: WH
authors: Ling
authors: P P
authors: PP
authors: Soe
authors: A S L
authors: AS
authors: Pang
authors: S-C
authors: SC
authors: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006509:Hepatitis B / Q000150:complications / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D014775:Virus Activation / Q000187:drug effects*; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil
references: Liver Int. 2004 Dec;24(6):540-6
references: 15566502
references: J Clin Oncol. 2006 Dec 1;24(34):5381-7
references: 17135639
references: Anticancer Res. 2004 Sep-Oct;24(5A):3035-40
references: 15517913
references: Hepatology. 2007 Feb;45(2):507-39
references: 17256718
references: Ann Intern Med. 2008 Apr 1;148(7):519-28
references: 18378948
references: Hepatology. 2009 May;49(5 Suppl):S156-65
references: 19399803
references: Gut. 1996;38 Suppl 2:S13-7
references: 8786046
references: Br J Cancer. 2011 Feb 15;104(4):559-63
references: 21285992
references: J Clin Oncol. 2009 Feb 1;27(4):591-8
references: 19075278
references: N Engl J Med. 2005 Jun 30;352(26):2696-704
references: 15987918
references: MMWR Recomm Rep. 2008 Sep 19;57(RR-8):1-20
references: 18802412
references: J Gastroenterol Hepatol. 1998 Jan;13(1):14-20
references: 9737566
references: J Viral Hepat. 2004 Jan;11(1):55-9
references: 14738558
references: Proc Natl Acad Sci U S A. 1986 Mar;83(6):1627-31
references: 3006059
references: J Clin Oncol. 2004 Jan 15;22(2):229-37
references: 14657227
references: J Med Virol. 2003 Aug;70(4):553-61
references: 12794717
references: Br J Cancer. 2004 Apr 5;90(7):1306-11
references: 15054446
references: J Clin Oncol. 2010 Jul 1;28(19):3199-202
references: 20516452
references: Korean J Intern Med. 2007 Dec;22(4):237-43
references: 18309681
references: Gastroenterology. 1991 Jan;100(1):182-8
references: 1983820
references: N Engl J Med. 2004 Mar 11;350(11):1118-29
references: 15014185
references: Gastroenterology. 1975 Jan;68(1):105-12
references: 1054319
references: Hepatology. 1992 Jul;16(1):13-8
references: 1319949
references: J Clin Oncol. 2011 Aug 20;29(24):3270-7
references: 21788556